April 7 (Reuters) - Ascletis Pharma Inc 1672.HK:
ASCLETIS ANNOUNCES FIXED-DOSE COMBINATION OF ASC30, ONCE-DAILY ORAL SMALL MOLECULE GLP-1R AGONIST, AND ASC39, ONCE-DAILY ORAL SMALL MOLECULE AMYLIN-SELECTIVE AMYLIN RECEPTOR AGONIST, FOR CLINICAL DEVELOPMENT
ASCLETIS PHARMA INC - EXPECTS IND SUBMISSION TO FDA FOR ASC30_39 FDC IN Q3 2026